Introduction {#section1-1479973120925430}
============

Lung cancer was estimated to cause over 1.7 million deaths worldwide in 2018, which made it the most frequent cause of death by cancer according to the Global Cancer Observatory estimates.^[@bibr1-1479973120925430]^ Chronic obstructive pulmonary disease (COPD) coexists in 50--70% of lung cancer patients.^[@bibr2-1479973120925430]^ The strong association between these conditions is partly the reflection of their shared risk factor, but COPD is also an independent risk factor for the occurrence of lung cancer even after controlling for tobacco exposure.^[@bibr3-1479973120925430]^ This suggests that the relationship between lung cancer and COPD goes beyond smoking, involving common inflammatory and genetics pathways.^[@bibr4-1479973120925430]^

The best treatment for early-stage non-small cell lung cancer remains curative-intent surgery.^[@bibr5-1479973120925430]^ However, surgical resection may be problematic in patients with impaired lung function. Prior studies of surgical outcomes in patients with COPD have not always relied on objective spirometric criteria.^[@bibr6-1479973120925430]^ A few studies described the postoperative outcome of patients with moderate-to-severe COPD; collectively, they highlighted a higher prevalence of complications.^[@bibr7-1479973120925430],[@bibr8-1479973120925430]^ Patients investigated for lung cancer with concomitant COPD have predominantly mild and moderate airflow limitation.^[@bibr9-1479973120925430]^ Recent studies explored the effect of the severity of COPD on surgical outcome but comprised only few patients with mild COPD.^[@bibr10-1479973120925430][@bibr11-1479973120925430]--[@bibr12-1479973120925430]^ Hence, the difference in postoperative outcome of patients suffering from varying severity of COPD is uncertain.

The objectives of this study were (1) to determine if the rate of postoperative complications is higher in patients with COPD compared to individuals with normal lung function; (2) to evaluate the influence of the severity of COPD on postoperative complications; and (3) to determine if the long-term survival is affected by the presence of COPD.

Methods {#section2-1479973120925430}
=======

Study population {#section3-1479973120925430}
----------------

The study population consisted of all lung cancer patients who underwent lung resection at the *Institut Universitaire de Cardiologie et de Pneumologie de Québec* (IUCPQ) between 2002 and 2012 and who provided written consent for their clinical data to be prospectively collected and archived for future research use in the institutional biobank clinical database. During this period, we estimate that more than 90% of lung resections for cancer in our institution were recorded in the biobank. The study was approved by the Institutional Ethics Committee (project CER 21184).

We included patients undergoing a first surgery for lung cancer with either normal pulmonary function or airflow limitation caused by COPD. COPD was defined as a forced expiratory volume in 1 s (FEV~1~) to forced vital capacity (FVC) ratio \<0.70 and a smoking history of at least 10 pack-years. Airflow limitation was stratified in severity according to the *Global Initiative for Chronic Obstructive Lung Disease* (GOLD) criteria^[@bibr13-1479973120925430]^ with FEV~1~ ≥ 80% predicted for mild COPD (GOLD 1), 50 ≤ FEV~1~ \< 80% for moderate COPD (GOLD 2), and 30 ≤ FEV~1~ \< 50% for severe COPD (GOLD 3). Post-bronchodilator FEV~1~ was used when available (42.3% of patients); otherwise pre-bronchodilator value was used. Patients were excluded if they previously had lung cancer or undergone lung resection, if they had asthma, abnormal lung function not caused by COPD, no spirometry available, or if they received at surgery a diagnosis of pulmonary metastasis, small cell lung cancer, carcinoid tumor, or benign tumor.

Data collection {#section4-1479973120925430}
---------------

The following information was extracted from the biobank's database: gender, age, body mass index (BMI), smoking history (in pack-years), pulmonary function tests, extent of lung resection, histopathologic diagnosis, and pathologic TNM staging. TNM staging established before 2010 was revised according to the AJCC seventh edition criteria.^[@bibr14-1479973120925430]^ Medical charts were reviewed to collect information about comorbidities, including coronary artery disease, peripheral artery disease, hypertension, dyslipidemia, diabetes, and chronic kidney disease. We also documented from the medical chart the surgical approach (thoracoscopy vs. thoracotomy), length of hospital stay, intensive care unit length of stay, pleural space drainage duration, and the occurrence of postoperative complications, including mechanical ventilation, pneumonia, pulmonary embolism, myocardial infarction, prolonged air leak (air leak \> 7 days), respiratory failure (defined as hypoxemic or hypercapnic respiratory failure), death, and any other complications not listed above. Postoperative complications were deemed to occur when mentioned in the discharge summary or in the medical record. Survival status until May 1, 2017, was obtained from the *Régie de l'assurance maladie du Québec* (RAMQ), a provincial organization to which all deaths occurring in the province of Québec are reported.

Statistical analysis {#section5-1479973120925430}
--------------------

Continuous descriptive and nominal variables are reported as means ± standard deviations (SD) and proportions, respectively. Proportions were analyzed using *χ* ^2^ or Fisher's exact test, whereas continuous variables were analyzed with one-way analysis of variance. Survival curves were constructed using Kaplan--Meier estimates and compared with the log-rank test. Cox proportional hazard regression analysis was performed to model event-free (death) at follow-up. Patient's characteristics were investigated to identify the prognostic factors that may explain the time until death event occur. Variables with a probability value \<0.20 were candidates for multivariate regression using a forward approach. Statistical significance was present with the two-tailed *p* value \<0.05.

Results {#section6-1479973120925430}
=======

Between 2002 and 2012, 1456 lung cancer resections were performed at the IUCPQ and were recorded in the biobank; 1126 patients met our inclusion criteria. The COPD group comprised 672 patients (59.7%), distributed in 340 GOLD 1, 282 GOLD 2, and 50 GOLD 3 patients. The remaining 454 patients, who had a normal respiratory function, formed the control group.

Patients' characteristics are presented in [Table 1](#table1-1479973120925430){ref-type="table"}. In the COPD group, we observed a lower proportion of women and patients were on average older than in the control group. Patients with COPD were heavier smokers and tended to exhibit more often peripheral artery disease, but this did not reach statistical significance. On the other hand, controls were more likely to undergo video-assisted thoracoscopic surgery than patients with COPD.

###### 

Patients' characteristics.

![](10.1177_1479973120925430-table1)

                                       COPD (*N* = 672)   Controls (*N* = 454)   *p* Value
  ------------------------------------ ------------------ ---------------------- -----------
  Women, *n* (%)                       277 (41.2)         259 (57.1)             \<0.0001
  Age (years)                          65.6 ± 8.3         62.3 ± 9.6             \<0.0001
  BMI (kg/m^2^)                        25.5 ± 4.7         26.7 ± 5.4             0.0002
  Current/former/never smoker (%)      31.3/68.8/0        22.3/68.1/9.7          \<0.0001
  Smoking history (pack-years)         50.2 ± 27.0        35.6 ± 26.2            \<0.0001
  Pulmonary function tests                                                       
   FEV~1~ (L)                          2.0 ± 0.6          2.5 ± 0.6              \<0.0001
   FEV~1~ (% predicted)                78.1 ± 17.3        99.9 ± 14.7            \<0.0001
   FVC (L)                             3.2 ± 0.8          3.3 ± 0.8              0.0476
   FVC (% predicted)                   98.3 ± 18.8        104.2 ± 15.6           \<0.0001
   FEV~1~/FVC                          60.8 ± 8.0         75.5 ± 4.8             \<0.0001
   TLC (L)                             6.2 ± 1.2          5.7 ± 1.2              \<0.0001
   TLC (% predicted)                   110.4 ± 15.3       106.2 ± 13.7           \<0.0001
   *D* ~LCO~ (ml/min/mmHg)             17.1 ± 5.1         19.6 ± 6.0             \<0.0001
   *D* ~LCO~ (% predicted)             81.7 ± 21.5        94.5 ± 22.4            \<0.0001
   RV (L)                              3.1 ± 3.8          2.4 ± 2.5              0.0003
   RV (% predicted)                    134.4 ± 38.3       114.2 ± 29.7           \<0.0001
  Coronary artery disease, *n* (%)     142 (21.1)         85 (18.7)              0.36
  Peripheral artery disease, *n* (%)   114 (17.0)         57 (12.6)              0.05
  Hypertension, *n* (%)                331 (49.3)         198 (43.6)             0.07
  Dyslipidemia, *n* (%)                283 (42.1)         190 (41.9)             0.95
  Diabetes, *n* (%)                    83 (12.4)          51 (11.2)              0.64
  Chronic kidney disease, *n* (%)      22 (3.3)           10 (2.2)               0.36
  VATS, *n* (%)                        247 (36.8)         203 (44.7)             0.0056
  Extent of resection, *n* (%)                                                   
   Pneumonectomy                       74 (11.0)          43 (9.5)               0.3428
   Bilobectomy                         67 (10.0)          47 (10.4)              
   Lobectomy                           456 (67.9)         328 (72.3)             
   Sublobar resection                  75 (11.1)          36 (7.9)               
  Histologic diagnosis, *n* (%)                                                  
   Adenocarcinoma                      408 (60.7)         316 (69.6)             0.0012
   Squamous cell carcinoma             229 (34.1)         106 (23.4)             
   Large-cell carcinoma                15 (2.2)           11 (2.4)               
   Other                               20 (3.0)           21 (4.6)               
  Pathologic staging, *n* (%)                                                    
   I                                   387 (57.6)         267 (58.8)             0.80
   II                                  168 (25.0)         109 (24.0)             
   III                                 108 (16.1)         69 (15.2)              
   IV                                  9 (1.3)            9 (2.0)                

FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; TLC: total lung capacity; *D* ~LCO~: diffusion capacity for carbon monoxide; RV: residual volume; VATS: video-assisted thoracoscopic surgery; BMI: body mass index.

The hospital (*p* = 0.0012) and intensive care unit length of stay (*p* = 0.0054) were significantly longer in COPD in comparison to controls ([Table 2](#table2-1479973120925430){ref-type="table"}). Pleural space drainage duration (*p* = 0.0029) was also significantly longer in COPD in comparison to controls ([Table 2](#table2-1479973120925430){ref-type="table"}). However, when comparing COPD GOLD 1, 2, and 3 groups, length of hospital stay, intensive care unit length of stay, and pleural space drainage duration were not statistically significantly different ([Table 3](#table3-1479973120925430){ref-type="table"}).

###### 

Postoperative outcomes in COPD and controls.

![](10.1177_1479973120925430-table2)

  Complications, *n* (%)             COPD (*N* = 672)   Controls (*N* = 454)   *p* Value
  ---------------------------------- ------------------ ---------------------- -----------
  Mechanical ventilation             30 (4.5)           12 (2.6)               0.15
  Pneumonia                          47 (7.0)           17 (3.7)               0.0251
  Pulmonary embolism                 6 (0.9)            2 (0.4)                0.49
  Myocardial infarction              3 (0.5)            0 (0.0)                0.28
  Prolonged air leak                 114 (17.0)         37 (8.2)               \<0.0001
  Respiratory failure                26 (3.9)           12 (2.6)               0.31
  Other morbidity                    254 (37.8)         136 (30.0)             0.0073
  Any complication                   329 (49.0)         160 (35.2)             \<0.0001
  30-Day mortality                   9 (1.3)            1 (0.2)                0.06
  Mortality during hospitalization   10 (1.5)           1 (0.2)                0.06
  Hospital length of stay (days)     9.6 ± 10.4         7.7 ± 8.8              0.0012
  ICU length of stay (days)^a^       3.0 ± 8.0          1.7 ± 3.2              0.0054
  Chest tube duration (days)^a^      5.9 ± 6.6          4.5 ± 5.5              0.0029

ICU: intensive care unit; COPD: chronic obstructive pulmonary disease.

^a^ Data obtained in 673/1126 and 706/1126 subjects, respectively.

###### 

Comparison of postoperative outcomes according to GOLD stage.

![](10.1177_1479973120925430-table3)

  Complications, *n* (%)             GOLD 1 (*N* = 340)   GOLD 2 (*N* = 282)   GOLD 3 (*N* = 50)   *p* Value
  ---------------------------------- -------------------- -------------------- ------------------- -----------
  Mechanical ventilation             15 (4.4)             12 (4.3)             3 (6.0)             0.77
  Pneumonia                          20 (5.9)             21 (7.5)             6 (12.0)            0.22
  Pulmonary embolism                 2 (0.6)              3 (1.1)              1 (2.0)             0.41
  Myocardial infarction              1 (0.3)              1 (0.4)              1 (2.0)             0.28
  Prolonged air leak                 54 (15.9)            49 (17.4)            11 (22.0)           0.51
  Respiratory failure                12 (3.5)             11 (3.9)             3 (6.0)             0.60
  Other morbidity                    117 (34.4)           117 (41.5)           20 (40.0)           0.18
  Any complications                  152 (44.7)           149 (52.8)           28 (56.0)           0.07
  30-Day mortality                   7 (2.1)              1 (0.4)              1 (2.0)             0.10
  Mortality during hospitalization   7 (2.1)              1 (0.4)              2 (4.0)             0.0425
  Hospital length of stay (days)     9.0 ± 10.6           10.2 ± 10.4          10.2 ± 8.5          0.45
  ICU length of stay (days)          2.8 ± 8.6            3.0 ± 7.5            3.7 ± 6.3           0.59
  Chest tube duration (days)         5.6 ± 5.8            6.0 ± 6.8            7.2 ± 10.0          0.21

ICU: intensive care unit.

The frequency of occurrence of any postoperative complications was significantly higher in patients with COPD than in controls (*p* \< 0.0001; [Table 2](#table2-1479973120925430){ref-type="table"}). In particular, pneumonia and prolonged air leak occurred significantly more frequently in COPD patients than in controls. There was a tendency for in-hospital mortality and 30-day mortality to be higher in patients with COPD, but this did not reach statistical significance.

Postoperative morbidity according to the GOLD airflow limitation grade is provided in [Table 3](#table3-1479973120925430){ref-type="table"}. Most patients were in the GOLD 1 and 2 categories, with only 50 patients in the GOLD 3 category. Even though the prevalence of most postoperative morbidity and mortality was numerically greater in the GOLD 3 category, none of the differences were statistically significant. We observed a higher in-hospital mortality in GOLD 3 patients (GOLD 1: 2.1% vs. GOLD 2: 0.4% vs. GOLD 3: 4.0%; *p* = 0.0425) but the 30-day mortality was not statistically significantly different across the different GOLD categories.

Current or previous smoking history, cumulative tobacco exposure, age, a diagnosis of COPD, the presence of coronary or peripheral artery disease, diabetes, the need for thoracotomy, the need for pneumonectomy or bilobectomy versus lobectomy, pathological TNM stage II, III, or IV, and GOLD stage 1 or 2 were all associated with long-term mortality in the univariate analyses ([Table 4](#table4-1479973120925430){ref-type="table"}). However, in the multivariate analysis, the effect of COPD on mortality was lost, with age, cumulative tobacco exposure, the presence of coronary artery disease, and pathological TNM stage II, III, or IV remaining as the only predictors of mortality ([Table 5](#table5-1479973120925430){ref-type="table"}). There was no significant impact of GOLD category on mortality. A Kaplan--Meier analysis of long-term survival in patients with COPD and controls is shown in [Figure 1](#fig1-1479973120925430){ref-type="fig"}. During the follow-up period, 389 patients with COPD and 213 controls died. Patients with COPD had lower survival compared to controls; however, when the curves were adjusted for mortality predictors in the multivariate analysis, long-term survival was similar between the two groups.

###### 

Univariate predictors of mortality.

![](10.1177_1479973120925430-table4)

  Covariate                         Hazard ratio   95% Confidence intervals   *p* Value
  --------------------------------- -------------- -------------------------- -----------
  Women                             0.72           0.61--0.84                 \<0.0001
  Former smoker                     1.98           1.14--3.45                 0.0150
  Current smoker                    2.35           1.34--4.13                 0.0029
  Pack-years                        1.01           1.01--1.01                 \<0.0001
  Age (years)                       1.03           1.02--1.03                 \<0.0001
  BMI (kg/m^2^)                     1.00           0.98--1.01                 0.75
  COPD                              1.30           1.10--1.54                 0.0019
  Coronary artery disease           1.48           1.23--1.78                 \<0.0001
  Peripheral artery disease         1.31           1.06--1.61                 0.0111
  Hypertension                      1.04           0.89--1.22                 0.62
  Dyslipidemia                      1.06           0.90--1.25                 0.49
  Diabetes                          1.43           1.14--1.80                 0.0020
  Chronic kidney disease            1.30           0.83--2.03                 0.25
  Thoracotomy                       1.45           1.21--1.73                 \<0.0001
  Extent of resection                                                         
   Pneumonectomy versus lobectomy   1.86           1.46--2.36                 \<0.0001
   Bilobectomy versus lobectomy     1.49           1.16--1.91                 0.0017
  Pathological TNM stage                                                      
   II                               1.71           1.41--2.06                 \< 0.0001
   III                              2.92           2.37--3.59                 \< 0.0001
   IV                               1.89           1.08--3.30                 0.0248
  Histologic diagnosis                                                        
   Adenocarcinoma                   0.55           0.37--0.81                 0.0022
   Squamous cell carcinoma          0.78           0.52--1.15                 0.21
   Large cell carcinoma             0.75           0.41--1.39                 0.36
  GOLD stage                                                                  
   GOLD 1                           1.23           1.01--1.49                 0.0395
   GOLD 2                           1.42           1.16--1.74                 0.0006
   GOLD 3                           1.19           0.79--1.79                 0.40

GOLD: Global Initiative for Chronic Obstructive Lung Disease; COPD: chronic obstructive pulmonary disease; BMI: body mass index.

###### 

Multivariate predictors of mortality.

![](10.1177_1479973120925430-table5)

  Covariate                 Hazard ratio   95% Confidence intervals   *p* Value
  ------------------------- -------------- -------------------------- -----------
  Age (years)               1.02           1.01--1.03                 \<0.0001
  Pack-years                1.01           1.00--1.01                 0.0003
  Coronary artery disease   1.43           1.17--1.74                 0.0004
  Thoracotomy               1.08           0.89--1.31                 0.42
  Pathological TNM stage                                              
   Stage II                 1.65           1.35--2.02                 \<0.0001
   Stage III                3.08           2.47--3.85                 \<0.0001
   Stage IV                 2.32           1.29--4.16                 0.0048
  GOLD stage                                                          0.4710
   GOLD 1                   1.02           0.83--1.25                 0.88
   GOLD 2                   1.11           0.90--1.38                 0.33
   GOLD 3                   1.33           0.88--2.03                 0.18

GOLD: Global Initiative for Chronic Obstructive Lung Disease.

![(a) Unadjusted and (b) adjusted Kaplan--Meier curves for long-term survival in COPD patients and controls. Covariates include age, smoking history (pack-years), coronary artery disease, and TNM stages. COPD: chronic obstructive pulmonary disease.](10.1177_1479973120925430-fig1){#fig1-1479973120925430}

Discussion {#section7-1479973120925430}
==========

In this study, we found that COPD was highly prevalent among patients with lung cancer undergoing thoracic surgery. Patients with COPD were more likely to suffer from postoperative morbidities, especially from pneumonia and prolonged air leak, than those having a normal respiratory function. COPD severity did not influence the occurrence of postoperative morbidity. While long-term survival appeared inferior in patients with COPD, this survival disadvantage disappeared once mortality predictors in the multivariate analysis, with age, pack-years, coronary artery disease, and TNM pathological stage were taken into account.

Our study adds to the literature because we have a large and a well-characterized study population, including an objective spirometric assessment of lung function in all study participants. Another positive feature of our study is the considerable size of the GOLD 1 and GOLD 2 groups. The high COPD prevalence (60%) we found in this population with lung cancer undergoing surgical resection is in agreement with the one in patients with newly diagnosed lung cancer reported by Loganathan et al.^[@bibr2-1479973120925430]^ Our data showing a higher prevalence of postoperative complications in patients with COPD compared to individuals with normal lung function including pneumonia and prolonged air leak is also consistent with previous reports.^[@bibr7-1479973120925430],[@bibr8-1479973120925430],[@bibr10-1479973120925430],[@bibr12-1479973120925430],[@bibr15-1479973120925430],[@bibr16-1479973120925430]^ A number of factors may explain why patients with COPD may be at increased risk of complications following lung resection, including advanced age, active smoking, limited ventilatory reserve, enhanced susceptibility to respiratory tract infection, and presence of comorbid conditions, such as coronary artery disease.^[@bibr5-1479973120925430]^

The overall 30-day and in-hospital mortality rates in control subjects (0.2%) and patients with COPD (1.5%) were low and within the expected mortality rates for lung cancer resection.^[@bibr17-1479973120925430]^ The small mortality signal in patients with GOLD 3 COPD is difficult to interpret given the small number of patients in this category and the low number of events (*n* = 2). An interesting finding of this study was that COPD was not independently associated with reduced long-term survival once confounders, such as age, smoking history, coronary artery disease, and TNM pathological stage, were considered. This highlights the importance of not considering the presence of COPD in isolation in the preoperative assessment of potential lung resection candidates but rather that all comorbidities should be weighted in the decisional process. In one study, the presence of self-reported physician diagnosed COPD was associated with reduced survival in patients undergoing lung cancer resection even when important covariates such as age, sex, and smoking history were taken into account.^[@bibr6-1479973120925430]^ However, this study was based on self-reported diagnosis of COPD. This is problematic because self-reported diagnosis of COPD may lead to both under- and overdiagnosis of COPD,^[@bibr18-1479973120925430],[@bibr19-1479973120925430]^ making it difficult to draw firm conclusions about the survival impact of COPD in a study, where this diagnosis was not confirmed by spirometry. In two studies in which objective assessment of COPD was obtained, survival following lung resection was not reduced in the presence of GOLD 1 and 2 COPD.^[@bibr10-1479973120925430],[@bibr20-1479973120925430]^ In contrast to our findings, these two studies reported that GOLD 3 COPD was associated with poorer long-term survival compared to individuals with normal lung function. Similar to the present study, the number of patients with GOLD 3 COPD was small in these two previous studies (*n* = 36 and *n* = 51, respectively). The differences between their and our study could also be explained by differences in the patient selection process, leading to variations in the physical fitness of patients with GOLD 3 COPD across studies. Together, the present and previous studies support that patients with mild-to-moderate COPD should not be denied surgical lung resection solely on the presence of COPD. Whether lung resection surgery can be offered in a safe manner to patients with severe COPD cannot be currently ascertained because of the small number of patients involved. This decision should be carefully considered on an individual basis by medical and surgical teams.

Our retrospective study has limitations however. Only a small number of patients with GOLD 3 COPD were involved, a reflection of the preoperative patient selection process. Quality of life was not measured. This issue of quality of life has already been studied by Pompili et al.^[@bibr21-1479973120925430]^ who reported, in a small group of patients, that postoperative quality of life (measured by a questionnaire) in patients with moderate and severe COPD was comparable to that of patients with normal respiratory function. Due to the retrospective design of our study, there were some missing information regarding the intensive care unit length of stay and chest tube duration that could not be retrieved from the medical chart in all patients. Also, postoperative complications were deemed to occur when mentioned in the discharge summary or medical record, without the use of standardized definition, leaving the possibility of misdiagnosis for some of them. Finally, whether selection bias in our cohort exists is uncertain. In our institution, standard preoperative evaluation protocols are followed, as recommended by official organizations such as the American College of Chest Physicians.^[@bibr5-1479973120925430]^ Only patients who were considered fit for surgery underwent lung resection. This could explain the favorable postoperative outcome and low mortality rate in this cohort. Nevertheless, this information provides reassurance that these recommendations lead to safe thoracic surgical procedures in patients with mild-to-moderate COPD.

Conclusion {#section8-1479973120925430}
==========

Patients with mild-to-moderate COPD were at higher risk of post lung resection complications, in particular, pneumonia and persistent air leak compared to patients with a normal respiratory function. These findings should help inform clinicians in their decision to offer surgical lung resection in individuals with COPD. The prevention and early detection of postoperative complications could be the next step to improve the postoperative outcome of this group of patients. Future studies should also explore if these results could be extended to patients with severe COPD.
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